Key Highlights
- First quarter revenue reached $15.29B, surpassing the $14.94B consensus forecast
- Core earnings per share registered at $2.58, exceeding the $2.54 analyst projection
- Oncology division delivered 16% year-over-year growth; rare disease segment climbed 15%
- Company reaffirms full-year outlook: mid-to-high single-digit revenue expansion, low double-digit core EPS advancement
- Shares declined approximately 1% following results, with market watchers attributing this to expectations already baked into valuations
Wednesday brought a robust earnings report from AstraZeneca, though investors responded with measured restraint. The British pharmaceutical giant delivered first-quarter revenue totaling $15.29 billion, marking an increase from the prior year’s $13.59 billion and surpassing the $14.94 billion analyst projection.
AstraZeneca $AZN Q1 revenue rose to $15.29B, above the $14.94B estimate, as strong cancer and rare-disease drug sales lifted results. Oncology now makes up about 44% of revenue. Core EPS was $2.58 vs. $2.54 est., and the company kept full-year guidance.
— Wall St Engine (@wallstengine) April 29, 2026
Core earnings per share registered at $2.58, topping the $2.54 forecast. Core operating profit advanced 12% to reach $4.25 billion.
The earnings beat failed to lift the stock, with AZN shares declining roughly 1% during morning London trading hours. eToro analyst Adam Vettese characterized the market reaction as “muted,” explaining that investors had already factored in the company’s positive trajectory.
The oncology division continues powering corporate performance, representing 44% of total group revenue. This segment generated sales growth of 16% year-over-year at constant currency rates, reaching $6.8 billion.
Imfinzi, prescribed for bladder and lung cancer treatment, climbed 30% to $1.7 billion. Tagrisso, a lung cancer medication, advanced 5% to $1.8 billion. Enhertu, targeting breast and gastric cancers, soared 34% to $831 million.
The rare disease division also posted strong performance, with sales advancing 15% compared to the previous year.
Oncology and Specialty Medicines Power Quarterly Performance
Revenue from U.S. operations expanded 10% during the quarter, while Chinese market sales increased 2%. AstraZeneca has executed significant strategic initiatives across both territories throughout the past year, including a $50 billion U.S. manufacturing agreement and a $15 billion investment pledge in China.
The pharmaceutical company additionally obtained an NYSE listing and secured U.S. tariff exemptions via a drug pricing arrangement.
Net profit for the first quarter climbed to $3.08 billion from $2.92 billion in the corresponding period last year.
Development Pipeline and Long-Term Vision Remain Intact
Chief Executive Pascal Soriot reinforced the company’s $80 billion annual revenue objective for 2030. He indicated AstraZeneca is positioning itself for numerous drug introductions and continues working toward more than 20 new product launches by that timeframe.
Three novel medications could enter the U.S. market this year subject to regulatory clearance: baxdrostat for hypertension management, camizestrant for a specific breast cancer variant, and gefurulimab for a chronic autoimmune condition.
The company maintained its full-year 2026 outlook without modifications. AstraZeneca anticipates mid-to-high single-digit revenue expansion and low double-digit core EPS growth measured at constant currencies.
Soriot cautioned last week that Europe faces potential relegation to a “sales office” role within the pharmaceutical sector as the continent lags behind the U.S. and China. This perspective informs AstraZeneca’s ongoing strategy to strengthen its presence across both major markets.
LSEG analysts project full-year 2026 sales expansion of 7.2% and profit growth of 11.2%, largely consistent with 2025 performance levels.
AstraZeneca’s shares have remained essentially unchanged year-to-date entering today’s earnings release. The positive results did little to alter that trajectory.
